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OBJECTIVE To examine the effect of a peripherally active fatty acid amide hydrolase (FAAH) inhibitor ASP3652
on safety and efficacy outcomes in chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS).
Inhibition of FAAH is hypothesized to reduce the excitability of urinary tract afferents includ-
ing nociceptors.
MATERIALS AND
METHODS
In this adaptive, randomized, double-blind, placebo-controlled study, adult male patients with mod-
erate to severe CP/CPPS were treated for 12 weeks with an oral dose of ASP3652 (25, 75, 150,
or 300 mg twice daily, or 300 mg once daily), or placebo. A Bayesian model was used for adap-
tive prospective modeling of randomization, study continuation decisions, and analysis of the ef-
ficacy variables.
RESULTS The study was stopped for futility at preplanned interim analysis when 239 patients were ran-
domized (226 were included in the intention-to-treat set): the 25 mg group showed the largest
reduction of the primary end point National Institutes of Health Chronic Prostatitis Symptom
Index total score (7.0 points), but the placebo group showed a mean reduction of 7.3 points (dif-
ference: 0.3 [95% confidence interval: −1.9, 2.6]). Micturition outcomes improved compared with
placebo in all ASP3652 groups; for example, in the 300 mg twice daily group, voiding frequency
decreased by −1.10 (95% CI: −2.0, −0.2) voids/24 hours vs placebo. Safety outcomes were com-
parable across the treatment groups.
CONCLUSION ASP3652 was generally safe and well-tolerated. It did not show efficacy on pain symptoms in pa-
tients with CP/CPPS. However, the results indicate that FAAH inhibition may attenuate lower
urinary tract symptoms. Dedicated studies in patients with lower urinary tract dysfunction are needed
to confirm this. UROLOGY ■■: ■■–■■, 2017. © 2017 Elsevier Inc.
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Chronic prostatitis/chronic pelvic pain syndrome(CP/CPPS) is a common urologic diagnosis in menand is associated with significant pain, urinary
symptoms, and reduction in quality of life (QoL).1 Suc-
cessful management of this condition is challenging and
often inadequate, indicating a need to develop novel and
effective therapies.1,2
Fatty acid amide hydrolase (FAAH) is a synaptic mem-
brane enzyme responsible for the breakdown of endog-
enous cannabinoids (eCBs). Naturally occurring eCBs and
exogenous cannabinoids such as delta-9-tetrahydrocannabinol
directly stimulate cannabinoid receptors, including recep-
tor subtypes CB1 and CB2.3,4 Activation of the CB1 recep-
tor reduces activity and excitability of nociceptors.5,6
By inhibiting FAAH, the levels of eCBs at activated
sites (eg, local afferent nerves) are hypothesized to in-
crease, thereby reducing pain in CP/CPPS. Treatment with
centrally acting CB agonists can induce cannabinoid-
like side effects, such as psychoactive and motor effects.7
Peripheral FAAH inhibition may not induce these central
effects. ASP3652 is an orally available small molecule
FAAH inhibitor with minimal central nervous system pen-
etration. Internal Astellas data from animal models showed
ASP3652 to be active on pain, voiding frequency, and
bladder volume. ASP3652 appeared to increase eCBs in
a dose-dependent way in plasma and to have a good safety
profile in various healthy human volunteer studies in which
more than 350 subjects were exposed to ASP3652 (Inter-
nal Astellas data).
MATERIALS AND METHODS
This was an adaptive, randomized, double-blind, placebo-
controlled, parallel group,multidose level clinical trial with a treat-
ment period of 12 weeks (ClinicalTrials.gov Identifier:
NCT01391338). Adult male patients with CP/CPPS8 of mod-
erate to severe intensity were enrolled. Key selection criteria are
presented in Supplementary Table S1. The protocol and amend-
ments were reviewed by an independent ethics committee for each
study site. Approval for the study protocol was obtained from the
relevant competent authorities prior to study initiation. The study
was conducted in accordance with the ethical principles that have
their origin in the 1964Declaration ofHelsinki and its later amend-
ments, Good Clinical Practice, International Conference on
Harmonisation, guidelines, and applicable laws and regulations.
An independent ethics committee-approved written informed
consent was obtained from all individual participants included
in the study prior to the initiation of any study-specific procedures.
During the treatment period, the patients received ASP3652
(25, 75, 150, or 300 mg twice daily, or 300 mg once daily) or
matching placebo. The dose range for the study was selected based
on modeling and simulation of nonclinical and phase 1 clinical
pharmacokinetic and pharmacodynamic data. The study was con-
ducted between June 2011 and February 2013 at 35 centers in 6
European countries (Czech Republic, Germany, Latvia, Lithu-
ania, Poland, and Spain).
The primary end point was change in total score from base-
line to week 12 in the National Institutes of Health Chronic Pros-
tatitis Symptom Index (NIH-CPSI).9,10 This score combines aspects
of 3 important symptom domains of CP/CPPS (pain, micturi-
tion, and QoL), with higher scores indicating higher disease se-
verity. A key secondary outcome was mean daily pain: the mean
of average daily pain severity scores (on a 0-10 numerical rating
scale), measured on 7 consecutive days before study visits. Other
secondary efficacy parameters included International Prostate
Symptom Score (IPSS) and micturition diary parameters. During
the week prior to study visits, the patients were asked to com-
plete a 3-day voiding diary recording micturition episodes and
perceived level of urinary urgency by means of the Patient Per-
ception of Intensity of Urgency Scale.11
Clinical responders were defined as subjects who indicated
marked or moderate improvement on a 7-grade global response
assessment (GRA responders) and subjects who had a decrease
of 6 or more points in the primary end point (NIH-CPSI
responders).
To identify the effects of ASP3652 on mood and drug with-
drawal, specific questionnaires were incorporated, that is, the Profile
of Mood States questionnaire12 and Physician Withdrawal
Checklist.13
Statistical Design and Analyses
In clinical research, adaptive trial design has been proposed as
a means to increase the efficiency of randomized clinical trials.14
In the current study, a Bayesian (ie, prospective updating the prob-
ability for a hypothesis as more evidence or information becomes
available) adaptive trial design was employed to facilitate dose
selection by allocating most patients to the maximum effective
study group; it also enabled early stopping of the study if and when
outcomes were either very beneficial (“success”) or absent (“fu-
tility”). The Bayesian design used accumulating efficacy and safety
data for preplanned interim analyses to adjust the probability of
randomizing patients to individual treatment groups.15 An initial
“burn-in” period consisting of 60 randomized patients (10/
group, randomized 1:1:1:1:1:1) was performed. Thereafter, the ob-
served data at weeks 4, 8, and 12 were used for the interim analyses
for the next cohort of patients every 4 weeks favoring the
maximum effective dose, that is, the highest change from base-
line in primary and key secondary (NIH-CPSI pain domain) ef-
ficacy end points. In these calculations, drug safety was included
by considering withdrawals due to adverse event (AE) treat-
ment failures for whom change from baseline in end points was
set to 0 in the interim analyses. The allocation algorithm strived
to achieve a similar sample size in the placebo group and maximum
effective dose group. An independent data monitoring commit-
tee (DMC) performed the unblinded interim evaluations and made
recommendations to stop or continue the trial.
The sample size for this study was explored through Bayesian
clinical trial simulations: assuming that at least 1 dose group
achieved a clinically relevant effect in the NIH-CPSI total score
compared with placebo (ie, reduction of 4 points or more10) and
a standard deviation of 7, a total of 350 subjects would be suf-
ficient to demonstrate that the probability that the best dose is
found to be superior to placebo is at least 95%.
Bayesian posterior predictive probabilities (ranging from 0 to
1) were calculated for the adaptive interim analyses as well as
for the final analysis at the end of the study. The probability that
a certain dose was better than placebo was used, either by the
futility difference (ie, a mean difference vs placebo of ≥2 points
in the NIH-CPSI total score) or by the clinical significant dif-
ference (CSD). After 50% of the patients were randomized, the
study would be stopped for success if the probability by CSD was
at least 90%. The study would be stopped for futility if the prob-
ability by futility difference was less than 20%.
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Continuous secondary and exploratory variables were ana-
lyzed using non-Bayesian analysis of covariance models. A lo-
gistic regression model was used to analyze the proportion of
NIH-CPSI and GRA responders. “Last observation carried forward”
was utilized to impute missing values. Odds ratios (ORs) of each
ASP3652 treatment group over placebo and the corresponding
2-sided 95% CI were derived. The study was powered using Bayes-
ian statistics, therefore not designed to test a statistical hypoth-
esis at any significant level; P values are therefore for the purpose
of flagging potential trends only, not for rigorous assessment of
statistical significance.
All non-Bayesian data processing, summarization, and analy-
ses were performed using Statistical Analysis System (SAS in-
stitute Inc; Cary, NC, USA) or above in a Unix environment.
Bayesian interim and final analyses were performed using program
scripts in Fortran in a Linux environment.
RESULTS
Participants
In total, 226 patients had evaluable primary end point mea-
surements (Fig. 1). Due to the adaptive randomization, the
final number of subjects per study group differed. One ran-
domized patient (300mg once daily) did not receive any study
medication. Demographic and baseline characteristics were
similar for all 6 treatment groups (Table 1). The mean age
of the patients was 45.4 years and the mean duration of CP/
CPPS symptoms was more than 4 years. Pharmacody-
namic analysis in subjects receiving ASP3652 showed a dose-
dependent increase of eCB serum levels (data not shown).
Efficacy
After 239 patients were randomized, the study was stopped
for futility at the recommendation of the DMC. The ef-
ficacy population (N = 226) included patients with an as-
sessable primary end point, that is, a baseline and at least
1 post-baseline NIH-CPSI total score, or withdrew due to
an AE, in which case the change from baseline in the
primary end point was set to 0. The results of the Bayes-
ian analysis allocated most subjects to the 25 mg twice daily
dose (n = 52); this group showed a mean change from base-
line to end of treatment of −7.0 points of the NIH-CPSI
total score (Table 2). However, the mean decrease in the
placebo group was −7.3 (calculated posterior difference: 0.3
[95% CI: −1.9, 2.6]). The probability that this dose was
better than placebo was 1.9%, that is, lower than the pre-
defined margin probability for stopping for futility (20%).
The probability that the 25 mg dose was better than placebo
by the CSD was less than 0.1%.
No dose-response relationship in primary and key sec-
ondary end point was observed. Also, no marked differ-
ences were observed between placebo and ASP3652 groups
in QoL NIH-CPSI subdomain scores, mean daily pain
(Table 2), as well as in the NIH-CPSI responder rates: 64%
vs 50%-56%, respectively (OR ranging from 0.62 [95% CI:
0.24, 1.57] to 0.89 [95% CI: 0.33, 2.43]). For GRA, the
responder rate was 38% vs 39%-50%, respectively (OR
ranging from 0.87 [95% CI: 0.39, 1.96] to 1.79 [95% CI:
0.73, 4.41]). No treatment effect was shown in the
preplanned subgroups.
The adjusted mean changes of outcomes relating to mic-
turition appeared to be larger in all ASP3652 groups than
in the placebo group. For these outcomes, the P values for
the difference with placebo were smaller than .05 for some
of the study groups (Table 2). Other derived micturition
parameters (ie, nocturnal voids, mean level of urgency) also
Figure 1. Flow diagram of study population (safety and efficacy population). A, safety population: all randomized patients
who took at least 1 dose of double-blind study drug (N = 238; 1 patient in the 300 mg once daily dose group was ran-
domized but was not dosed); B, efficacy population: all randomized patients who took a dose of double-blind study drug
and had an National Institutes of Health Chronic Prostatitis Symptom Index total score at baseline and at least 1 post-
baseline or dropped out due to an adverse event (N = 226). (Color version available online.)
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showed the same pattern (data not shown). When design-
ing the study, it was not anticipated that the effect of
ASP3652 would be more prominent on micturition than
pain. As a result, no prospective subgroup analyses based
on micturition end points were planned, and no adjust-
ments for multiplicity of statistical analyses were deemed
necessary. A post-hoc analysis of 70 patients with in-
creased daily voiding frequency (see Table 1) showed that
the mean reduction in voids/24 hours in the ASP3652
groups ranged from −1.87 (95% CI: −3.21, −0.53) to −3.10
(95% CI: −5.40, −0.81) vs −0.65 (95% CI: −1.89, 0.58)
voids/24 hours in the placebo group.
Safety and Tolerability
Overall, 40.3% of the patients in this study experienced at
least 1 AE (41.1% in the placebo group and 40.1% in the
combinedASP3652 group;AEs related to study drug: 17.9%
and 16.5%, respectively). There were no clinically rel-
evant differences in specificAEs between placebo and study
drug groups. The most common AEs included headache
and insomnia (Supplementary Table S2). The incidence
of serious AEs was low (5 in total) and similar across all
groups, and none were considered to be related to the study
drug. None of the patients in the placebo group discon-
tinued treatment because of a drug related AE compared
to 7 (3.8%) in the total ASP3652 group (1 in 25 mg, 75 mg,
and 150 mg; 2 in 300 mg once daily and twice daily). No
dose-response relationship could be observed in AEs or
discontinuations.
No patients reported AEs related to mood changes, with-
drawal effects, or central nervous system effects in general.
The Profile of Mood States and Physician Withdrawal
Checklist questionnaires did not show differences between
placebo and ASP3652 (data not shown). Clinical labora-
tory evaluations, vital signs, and electrocardiograms did not
reveal any safety concerns with ASP3652 dosing.
COMMENT
To our knowledge, this is one of the first clinical studies
employing Bayesian adaptive trial design to be published
for a urologic condition. The adaptive design was effec-
tively performed and caused the study to stop early because
the peripheral FAAH inhibitor ASP3652 was found to be
not efficacious for CP/CPPS. By applying adaptive design
techniques, the efficiency of using patient data was in-
creased, saving 111 subjects from being treated with a drug
that was unlikely to reduce their pain. A disadvantage of
performing an adaptive study is the complexity of its imple-
mentation and execution,14 involving the complex logis-
tics of providing required data for the evaluation by the
DMC and its resulting ongoing randomization updates; it
therefore requires more lead time to set up than a classi-
cal study. However, this potential delay was effectively com-
pensated by the early study termination.
Overall, 5 dose levels of up to 300 mg twice daily were
safe and well-tolerated, but did not improve pain symp-
toms compared with placebo in men with moderate toT
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Table 2. Efficacy end points: values at baseline (mean [SE]), change from baseline to end of treatment (mean [SE]), and difference of change vs placebo (Δ vs placebo:
mean [95% CI; P value])
Variable Parameter
Placebo
N = 53
ASP3652
25 mg BID
N = 52
75 mg BID
N = 26
300 mg QD
N = 34
150 mg BID
N = 27
300 mg BID
N = 34
NIH-CPSI total score Baseline 24.2 (0.71) 23.4 (0.73) 22.3 (0.98) 23.5 (0.78) 21.2 (0.71) 22.4 (0.90)
EoT 17.0 (1.05) 16.1 (1.07) 14.9 (1.46) 16.6 (1.12) 13.8 (1.37) 15.6 (1.30)
CFB* −7.3 (0.97) −7.0 (0.68) −6.9 (0.69) −6.5 (0.78) −6.8 (0.60) −6.7 (0.70)
Δ vs PLC* – 0.3 (−1.9, 2.6) 0.4 (−1.9, 2.8) 0.7 (−1.7, 3.1) 0.5 (−1.7, 2.7) 0.6 (−1.8, 2.9)
Mean daily pain Baseline 5.1 (0.24) 4.8 (0.26) 4.5 (0.28) 4.9 (0.29) 3.9 (0.29) 4.7 (0.29)
CFB −1.4 (0.25) −1.3 (0.26) −1.0 (0.35) −1.1 (0.34) −1.7 (0.37) −1.1 (0.32)
Δ vs PLC – 0.1 (−0.6, 0.8; 0.78) 0.3 (−0.5, 1.2; 0.44) 0.3 (−0.6, 1.1; 0.55) −0.4 (−1.2, 0.5; 0.43) 0.2 (−0.5, 1.0; 0.54)
NIH-CPSI pain
domain
Baseline 12.4 (0.38) 12.5 (0.38) 11.8 (0.54) 12.0 (0.42) 11.1 (0.45) 11.5 (0.43)
CFB −4.1 (0.50) −3.8 (0.52) −3.2 (0.73) −3.5 (0.66) −4.5 (0.74) −4.1 (0.66)
Δ vs PLC – 0.4 (−1.0, 1.8; 0.61) 1.0 (−0.8, 2.7; 0.28) 0.6 (−1.0, 2.3; 0.45) −0.3 (−2.1, 1.4; 0.70) 0.0 (−1.6, 1.6; 0.99)
NIH-CPSI urinary
domain
Baseline 3.4 (0.33) 3.1 (0.29) 3.0 (0.41) 3.8 (0.33) 2.5 (0.35) 3.1 (0.44)
CFB −0.5 (0.25) −0.7 (0.26) −1.5 (0.36) −1.2 (0.33) −0.6 (0.37) −0.8 (0.33)
Δ vs PLC – −0.2 (−0.9, 0.5; 0.57) −1.0 (−1.9, −0.1; 0.028) −0.7 (−1.5, 0.1; 0.080) −0.1 (−1.0, 0.8; 0.81) −0.3 (−1.1, 0.5; 0.45)
NIH-CPSI QoL
domain
Baseline 8.4 (0.30) 7.8 (0.35) 7.5 (0.39) 7.8 (0.40) 7.6 (0.34) 7.8 (0.33)
CFB −2.1 (0.35) −2.6 (0.35) −2.5 (0.50) −1.9 (0.45) −3.1 (0.50) −2.5 (0.45)
Δ vs PLC – −0.5 (−1.5, 0.4; 0.28) −0.4 (−1.6, 0.8; 0.51) 0.2 (−0.9, 1.3; 0.72) −1.0 (−2.2, 0.2; 0.10) −0.4 (−1.5, 0.7; 0.51)
Voids per 24 hours Baseline 7.37 (0.52) 6.90 (0.58) 6.75 (0.67) 7.17 (0.43) 6.60 (0.87) 6.67 (0.50)
CFB 0.09 (0.30) −0.46 (0.31) −0.63 (0.44) −0.60 (0.40) −0.52 (0.44) −1.00 (0.37)
Δ vs PLC – −0.56 (−1.4, 0.3; 0.20) −0.72 (−1.8, 0.3; 0.18) −0.69 (−1.7, 0.3; 0.16) −0.61 (−1.7, 0.4; 0.25) −1.10 (−2.0, −0.2; 0.022)
Urgency episodes†
per 24 hours
Baseline 1.21 (0.29) 0.61 (0.21) 0.70 (0.21) 0.91 (0.18) 1.31 (0.43) 0.92 (0.25)
CFB 0.01 (0.17) −0.27 (0.18) −0.42 (0.24) −0.30 (0.22) −0.68 (0.24) −0.24 (0.21)
Δ vs PLC – −0.28 (−0.77, 0.20; 0.26) −0.43 (−1.02, 0.16; 0.15) −0.31 (−0.86, 0.23; 0.26) −0.69 (−1.28, −0.10; 0.022) −0.26 (−0.78, 0.27; 0.34)
IPSS total score Baseline 7.22 (0.56) 7.54 (0.59) 8.88 (1.04) 8.82 (0.75) 6.32 (0.83) 8.39 (0.89)
CFB −0.01 (0.64) −0.24 (0.66) −2.25 (0.91) −2.04 (0.85) −1.01 (0.91) −1.43 (0.82)
Δ vs PLC – −0.24 (−2.05, 1.57; 0.79) −2.25 (−4.46, −0.04; 0.046) −2.04 (−4.14, 0.07; 0.058) −1.00 (−3.20, 1.19; 0.37) −1.42 (−3.47, 0.62; 0.17)
ANCOVA, analysis of covariance; CFB, change from baseline; CI, confidence interval; EoT, end of treatment; IPSS, International Prostate Symptom Score; NIH-CPSI, National Institutes of Health Chronic Prostatitis Symptom
Index; PLC, placebo; QoL, quality of life; SE, standard error.
Secondary end points: the ANCOVA model for CFB is generated with 2 factors (treatment group and country) and 1 covariate (baseline score).
* NIH-CPSI total score data are outcomes of Bayesian modeling, CIs are predicted intervals, and no P values were calculated in the Bayesian analysis.
† Urgency episode: voiding episode with a urgency severity grade 3 or 4 on the PPIUS scale.
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severe CP/CPPS. This lack of analgesic effect of FAAH
inhibition was observed earlier in humans with chronic pain,
contrasting data from animal models.16 In the current study,
the percentages of responders based on the NIH-CPSI total
score were even higher in the placebo group compared with
the ASP3652 groups. However, response based on global
improvement (ie, GRA) seemed to be somewhat higher
in ASP3652, with ORs of up to 1.79. The NIH-CPSI score
is heavily dependent on pain,17 whereas the global clini-
cal response measured with the GRA may weigh symp-
toms other than pain, for example, lower urinary tract
symptoms (LUTS).
The placebo response on NIH-CPSI total score
(6.7/24.2 = 27.7%) and pain domain (4.1/12.4 = 33.1%)
were in line with publications on CP/CPPS with compa-
rable study populations and therapy duration.18-20 The
placebo response on the urinary domain was relatively
smaller (14.7%) but still within the range of earlier
CP/CPPS publications.21-23 On micturition diary param-
eters and IPSS, however, the placebo group did not show
a considerable reduction. The patient information pro-
vided before study enrollment did not focus on an expected
effect on micturition. And other than in bladder pain
syndrome, the pain in CP/CPPS is not necessarily per-
ceived to be related to voiding. The patients in the
current study possibly did not expect effects on micturi-
tion, which may explain the small placebo response on
micturition outcomes.
Patients with significant LUTS (ie, IPSS ≥20) were ex-
cluded from the study to select a homogenous population
avoiding confounding effects of voiding symptoms. There-
fore, the baseline urinary parameters were mild in this study
population, which is a limitation when examining drug
effects on LUTS. Notwithstanding this mild urinary profile,
the ASP3652 treated groups showed improvement of LUT
parameters. The small placebo responses observed for urinary
symptoms probably enabled the detection of these treat-
ment effects. It has to be emphasized that the study was
powered to show effects on pain and not micturition, so
these effects on micturition must be interpreted with res-
ervation. Still the observations may be considered to have
some clinical relevance: the effects vs placebo on mictu-
rition frequency of ASP3652 in the total group and post-
hoc LUTS group were comparable with and even higher
than anticholinergic treatment in men with overactive
bladder.24
A recent review discusses the aggregated data on the role
of the endocannabinoid system in micturition and LUTS
in preclinical studies, and concluded that modification of
a local endogenous sensitized signal in micturition path-
ways would indeed be an attractive pharmacologic prin-
ciple to relieve LUTS.25 A beneficial effect on bladder
capacity may underlie the urinary effects of ASP3652. In
humans, a placebo-controlled study in 135 multiple scle-
rosis patients with overactive bladder cannabis extract
showed to significantly improve urinary symptoms, includ-
ing frequency and nocturia.26 The current study was not
designed to show effects on LUTS, so it would therefore
be interesting to examine the effects of ASP3652 on mic-
turition in a population with true LUT dysfunction.
CONCLUSION
The peripheral FAAH inhibitor ASP3652 was generally
safe and well-tolerated. It did not show efficacy on pain
symptoms in patients with moderate to severe CP/CPPS.
However, the results suggest that FAAH inhibition may
attenuate LUTS, which should be examined in dedi-
cated studies.
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